Nurix Therapeutics heads into today's earnings print as one of the more heavily shorted names in clinical-stage biotech, with short sellers retaining a firm grip on the stock.
Short interest is running at roughly 21.9% of free float — a level that climbed sharply from around 18.7% in early April and has held near that elevated plateau ever since. The rise of roughly 17% over the past month represents a clear escalation in bearish positioning, not noise. Yet the borrow market tells a more nuanced story: the cost to borrow remains very low at just 0.50% annualised, and availability is wide, meaning new shorts face virtually no friction entering positions. That combination — high SI, low cost, ample availability — describes a stock where bears are comfortable but not yet under pressure. The ORTEX short score of 67.4 out of 100 corroborates the picture: elevated, but not at an extreme that would signal imminent squeeze risk. Options positioning has also shifted noticeably more defensive over the past two weeks, with the put/call ratio climbing to 0.67, near its 52-week high and well above its 20-day average of 0.57.
The Street, however, is firmly in the bull camp. All active analyst ratings are Buy or Overweight, with a consensus price target near $30 — nearly double the current price of $16. Wells Fargo trimmed its target modestly to $28 in April while maintaining Overweight, and both HC Wainwright and Needham reiterated Buy ratings after the most recent data readout. Bulls point to Nurix's proprietary targeted protein degradation platform, its AI-integrated ligase discovery engine, and deep-pocketed partnerships with Pfizer/Seagen, Gilead, and Sanofi as the foundation for long-term value. Bears counter that the company is pre-profit — burning roughly $264 million in operating cash annually on estimated revenue of only $53 million — and that clinical failure or a partner pullback could rapidly erode the thesis. The enterprise value already prices in a great deal of future success for a company still in the clinic.
Institutional ownership reinforces a longer-term constructive tilt. BlackRock added more than 2.1 million shares in the most recent reported period, lifting its stake to 8.6% of shares outstanding. Vanguard, Fidelity, and T. Rowe Price all added meaningfully as well. Insider activity is less encouraging near term: the CFO and Chief Legal Officer both sold in early May for proceeds in the low six figures, though at low significance scores, and the volumes are small relative to the broader ownership base.
Past earnings reactions have been asymmetric and occasionally sharp — the stock fell 9.4% on the day following the January 2026 print and then lost a further 14.7% over the following five sessions. Recoveries followed in subsequent quarters. Today's print will test whether the clinical pipeline milestones and partnership economics justify a valuation that the market is discounting heavily, and whether the elevated short base represents a potential catalyst or simply an informed crowd.
See the live data behind this article on ORTEX.
Open NRIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
